Drugs and FDA
FDA approves adrabetadex for infantile-onset Niemann-Pick disease
Lembaz is approved for patients weighing at least 7 kg whose symptoms began before age 6, with hearing evaluations recommended before and during treatment.

The FDA approved Lembaz, or adrabetadex, to reduce the risk of death in adults and children with infantile-onset Niemann-Pick disease type C whose neurological symptoms began before age 6. Patients must weigh at least 7 kg (about 15 pounds). A healthcare provider gives the treatment by injection into the spinal canal every two weeks.
The FDA said its review included survival data for 36 treated patients across three clinical studies and an expanded access program. Compared with matched external controls, treatment was associated with a 55% reduction in the risk of death. Median survival was 8.5 years among treated patients and 4.9 years in the control group. The survival finding was observed whether or not patients also took miglustat.
Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. The FDA recommends comprehensive hearing evaluations before treatment and regularly during treatment, and says dose adjustments may be needed based on results.
Reporting on this story
- MedPage Today FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder (opens in a new tab)
- FDA Drugs FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer (opens in a new tab)
- Medical Xpress FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival (opens in a new tab)


